Airway Disease Proteases
Airway Disease Proteases - Related Videos
09:00
Use of the Protease Fluorescent Detection Kit to Determine Protease Activity
0 Views •
Cited by 15 •
2009
The Protease Fluorescent Detection Kit is designed for the measurement of protease activity using fluorometry. It is also suitable for detection of trace amounts of protease contamination. The method is based on the proteolytic hydroysis of a proprietary formulation of a FITC-labeled casein substrate.
09:10
Heterotopic and Orthotopic Tracheal Transplantation in Mice used as Models to Study the Development of Obliterative Airway Disease
0 Views •
Cited by 7 •
2010
This video shows and compares two experimental models to study the development of obliterative airway disease (OAD) in mice, the heterotopic and orthotopic tracheal transplantation model.
11:37
Sigma's Non-specific Protease Activity Assay - Casein as a Substrate
0 Views •
Cited by 414 •
2008
Proteases break peptide bonds. In the lab, it is often necessary to measure and/or compare the activity of proteases. Sigma's non-specific protease activity assay may be used as a standardized procedure to determine the activity of proteases.
05:31
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
0 Views •
Cited by 4 •
2017
This protocol describes a noninvasive technique for the sampling of undisturbed mucosal lining fluid from the upper airways. It can be used to perform the quantification of in vivo levels of protein mediators, such as cytokines and chemokines, in subjects of all ages.
15:43
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
0 Views •
Cited by 78 •
2014
We describe the agar-beads method to establish persistent long-term chronic Pseudomonas aeruginosa airway infection in the mouse model.
FAQs
Endogenous antiproteases normally restrain proteolytic activity, helping limit unnecessary damage in respiratory tissues. When this balance shifts toward excessive or poorly controlled enzyme activity, structural proteins and regulatory molecules may be cleaved more extensively. The resulting loss of control can intensify inflammation, weaken airway barriers, and promote tissue injury, making protease-antiprotease balance an important disease mechanism.
Airway disease proteases can act on several functionally different targets, including extracellular-matrix proteins, epithelial junction components, mucus-associated proteins, and immune mediators. Cleavage of these targets may produce distinct consequences: altered tissue structure, reduced epithelial barrier integrity, changes in mucus behavior, or modified inflammatory signaling. Examining the target helps connect enzyme activity with a specific airway outcome.
Proteases made by airway or immune cells can reshape inflammation and injure respiratory tissue, while infectious microbes may contribute proteolytic activity within the same environment. Their combined effects can disturb host defense, alter barriers, and support pathogen spread. This interaction is especially relevant when studying infection-related lung damage, because tissue injury and microbial persistence may reinforce one another.
Asthma, chronic obstructive pulmonary disease, and infection-related lung damage are key contexts for investigating dysregulated airway proteolysis. Although the initiating causes differ, excessive enzyme activity may connect inflammation with impaired barrier function, remodeling, or tissue injury. Comparing these settings can help determine whether a protease-related finding reflects a shared mechanism or a disease-specific process.
Studies of airway disease proteases can identify enzyme activity or protease-related changes that reflect inflammation, barrier disruption, remodeling, or tissue injury. Such findings may support biomarker development by linking molecular activity with respiratory disease processes. A useful biomarker could help characterize disease biology, distinguish relevant pathways, or assess whether proteolytic activity is being controlled.
Protease inhibitors are investigated because they may reduce excessive or poorly controlled cleavage without requiring complete elimination of proteolytic activity. By restraining damaging activity, these therapies could help preserve epithelial barriers, limit tissue injury, and moderate inflammation. Their development depends on identifying proteases and substrates that contribute to disease while considering the normal role of proteolysis in airway defense.